The correlation between antiviral drug, immune response and HIV viral load
Abstract
Developing antiviral drugs is an exigent task since viruses mutate to overcome the effect of antiviral drugs. As a result, the efficacy of most antiviral drugs is short-lived. To include this effect, we modify the Neumann and Dahari model. Considering the fact that the efficacy of the antiviral drug varies in time, the differential equations introduced in the previous model systems are rewritten to study the correlation between the viral load and antiviral drug. The effect of antiviral drug that either prevents infection or stops the production of a virus is explored. First, the efficacy of the drug is considered to decreases monotonously as time progresses. In this case, our result depicts that when the efficacy of the drug is low, the viral load decreases and increases back in time revealing the effect of the antiviral drugs is short-lived. On the other hand, for the antiviral drug with high efficacy, the viral load, as well as the number of infected cells, monotonously decreases while the number of uninfected cells increases. The dependence of the critical drug efficacy on time is also explored. Moreover, the correlation between viral load, the antiviral drug, and CTL response is also explored. In this case, not only the dependence for the basic reproduction ratio on the model parameters is explored but also we analyze the critical drug efficacy as a function of time. We show that the term related to the basic reproduction ratio increases when the CTL response step up. A simple analytically solvable mathematical model is also presented to analyze the correlation between viral load and antiviral drugs.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Late treatment initiation leads to reduced antiviral potency
Xuanlin Liu, Evelyn J. Franco, … Anne‐Grete Märtson·bioRxiv·Sep 24, 2025
- Comparative efficacy of antiviral strategies targeting different stages of the viral life cycle: A viral quasispecies dynamics study
P. Lwin, G. R. Lewis, … B. A. Jones·bioRxiv·Oct 10, 2022
- Anti-proliferative therapy for HIV cure: a compound interest approach
D. Reeves, E. Duke, … J. Schiffer·bioRxiv·Jul 12, 2016
- Mathematical modeling of N-803 treatment in SIV-infected non-human primates
Jonathan W. Cody, Amy L. Ellis-Connell, … Elsje Pienaar·PLoS Computational BiologyPeer-reviewed·Jul 28, 2021
- Viral rebound kinetics following single and combination immunotherapy for HIV/SIV
Mélanie Prague, Jeffrey M. Gerold, … Alison L. Hill·bioRxiv·Aug 1, 2019
- Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion
Alan S. Perelson, Tin Phan, … Ruian Ke·PLoS PathogensPeer-reviewed·Jul 29, 2024